C4 TherapeuticsCCCC
About: C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Employees: 110
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
536% more call options, than puts
Call options by funds: $89K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
13% less funds holding
Funds holding: 114 [Q1] → 99 (-15) [Q2]
13.46% less ownership
Funds ownership: 90.3% [Q1] → 76.84% (-13.46%) [Q2]
24% less capital invested
Capital invested by funds: $103M [Q1] → $78M (-$24.5M) [Q2]
33% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 39
Research analyst outlook
We haven’t received any recent analyst ratings for CCCC.
Financial journalist opinion
Based on 3 articles about CCCC published over the past 30 days
